体内:Envafolimab(0.18-0.92 mg/kg;腹腔注射;2 周内四次)在 NOD-SCID 小鼠(A375 细胞)[3] 中表现出抗肿瘤活性,半衰期约为 72 小时。 参考文献: [1]. Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients ...